Supplier
Pajaro Valley Health Care District Hospital Corporation
Pajaro Valley Health Care District Hospital Corporation was paid $8.99M by Medicaid between Jun 2023 and Nov 2024, across 174 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 26% of everything it billed.
33Billing provider infoPAJARO VALLEY HEALTH CARE DISTRICT HOSPITAL CORPORATION
WATSONVILLE, CA 95076
WATSONVILLE, CA 95076
33aNPI1619607488assigned 06/14/2022
33bProvider typePharmacy
28Total paid$8.99M
24GClaims180,294
24DCodes billed174
24AFirst – last monthJun 2023 – Nov 2024
Compared with peers
Next to other Pharmacy providers in California
Rank by total paid#5 of 179
Median peer was paid$2K
This provider vs. median5,097×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 69,008 | $3.36M | |
| 2024incomplete | 111,286 | $5.63M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 26% | 27,292 | 24,676 | $2.31M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 1,632 | 1,603 | $491K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 1,528 | 1,490 | $347K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.9% | 1,999 | 1,999 | $347K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 3,365 | 3,191 | $342K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.2% | 3,991 | 3,895 | $291K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 5,156 | 4,693 | $231K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 2.3% | 290 | 288 | $211K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 3,027 | 2,879 | $177K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.8% | 1,306 | 1,305 | $165K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 1,308 | 1,233 | $158K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,329 | 2,193 | $146K |
162 more codes
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.6% | 211 | $146K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.5% | 724 | $139K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.5% | 1,269 | $138K |
| 76830 | Ultrasound, transvaginal | 1.4% | 1,167 | $127K |
| 80053 | Comprehensive metabolic panel | 1.4% | 9,320 | $126K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.4% | 147 | $122K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.3% | 1,284 | $119K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 377 | $114K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 1,789 | $113K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 1,116 | $108K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 1,814 | $99K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 2,933 | $98K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 9,725 | $97K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 3,351 | $91K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,995 | $88K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 545 | $86K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,371 | $71K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,255 | $70K |
| 93976 | <1% | 220 | $68K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 284 | $65K |
| 59025 | Fetal non-stress test | <1% | 1,047 | $65K |
| 93971 | <1% | 343 | $59K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 401 | $55K |
| 76801 | <1% | 599 | $54K | |
| V5008 | Hearing screening | <1% | 640 | $54K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 443 | $46K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 421 | $44K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 528 | $43K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 440 | $43K |
| 83605 | <1% | 2,754 | $43K | |
| 76642 | <1% | 482 | $42K | |
| 76770 | <1% | 361 | $42K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 471 | $41K |
| 81025 | <1% | 3,802 | $41K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 117 | $40K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 164 | $37K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 478 | $36K |
| 84484 | <1% | 2,106 | $33K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,775 | $32K |
| 77066 | Tomosynthesis, mammo | <1% | 162 | $31K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 18,590 | $28K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 340 | $28K |
| 83690 | <1% | 2,994 | $28K | |
| Z7502 | <1% | 683 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,443 | $26K |
| 73030 | <1% | 593 | $24K | |
| 73562 | <1% | 659 | $23K | |
| 73610 | <1% | 485 | $21K | |
| 81001 | <1% | 5,024 | $21K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 540 | $20K |
| 76536 | <1% | 219 | $20K | |
| 73630 | <1% | 494 | $19K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 59 | $18K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $18K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,046 | $17K |
| 72100 | <1% | 357 | $15K | |
| 83880 | <1% | 497 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 666 | $14K |
| 81002 | <1% | 2,727 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,871 | $14K |
| 73564 | <1% | 319 | $13K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 973 | $13K |
| 87040 | <1% | 568 | $12K | |
| 87186 | <1% | 1,028 | $12K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,022 | $12K |
| 84702 | <1% | 533 | $12K | |
| 93017 | <1% | 170 | $11K | |
| 77065 | Tomosynthesis, mammo | <1% | 80 | $11K |
| 86403 | <1% | 403 | $11K | |
| 86141 | <1% | 754 | $11K | |
| 87077 | <1% | 1,093 | $11K | |
| 76641 | <1% | 83 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 172 | $10K |
| 83735 | <1% | 1,153 | $10K | |
| 73130 | <1% | 232 | $9K | |
| 74018 | <1% | 314 | $9K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 670 | $9K |
| 73502 | <1% | 225 | $8K | |
| 82962 | <1% | 1,966 | $8K | |
| 76857 | <1% | 110 | $7K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 816 | $7K |
| 77080 | <1% | 151 | $7K | |
| 80061 | Lipid panel | <1% | 338 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 755 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 630 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 532 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 642 | $6K |
| Z9725 | <1% | 137 | $6K | |
| 87634 | <1% | 72 | $6K | |
| 80179 | <1% | 297 | $6K | |
| 72110 | <1% | 69 | $5K | |
| 82652 | <1% | 96 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 375 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 375 | $5K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 446 | $5K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 12 | $4K |
| 85610 | <1% | 763 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 273 | $4K |
| 84145 | <1% | 137 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 390 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 341 | $4K |
| 86850 | <1% | 274 | $3K | |
| 82728 | <1% | 158 | $3K | |
| 84466 | <1% | 162 | $3K | |
| 72040 | <1% | 77 | $3K | |
| 73560 | <1% | 117 | $3K | |
| 85730 | <1% | 383 | $3K | |
| 82570 | <1% | 347 | $3K | |
| 90715 | <1% | 40 | $3K | |
| 73110 | <1% | 63 | $3K | |
| 86901 | <1% | 616 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 309 | $2K |
| 85379 | <1% | 191 | $2K | |
| 76882 | <1% | 142 | $2K | |
| 82803 | <1% | 60 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 13 | $2K |
| 73140 | <1% | 79 | $2K | |
| 85027 | <1% | 207 | $2K | |
| 83540 | <1% | 175 | $2K | |
| 73590 | <1% | 54 | $2K | |
| 84703 | <1% | 131 | $1K | |
| Z7610 | <1% | 131 | $1K | |
| 87806 | <1% | 34 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 122 | $1K |
| 85651 | <1% | 206 | $1K | |
| 93350 | <1% | 13 | $1K | |
| 84156 | <1% | 259 | $1K | |
| 82247 | <1% | 155 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 74 | $1K |
| 76775 | <1% | 12 | $1K | |
| 86900 | <1% | 289 | $1K | |
| 82043 | <1% | 120 | $953.53 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 93 | $911.15 |
| 96367 | <1% | 15 | $844.58 | |
| 82248 | <1% | 103 | $781.65 | |
| 80069 | <1% | 64 | $766.65 | |
| 83655 | <1% | 62 | $733.04 | |
| 84100 | <1% | 105 | $655.08 | |
| 73080 | <1% | 13 | $642.43 | |
| 84439 | <1% | 43 | $487.45 | |
| 84153 | <1% | 15 | $427.50 | |
| 82550 | <1% | 57 | $406.84 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 49 | $373.77 |
| 82951 | <1% | 17 | $350.03 | |
| 0450 | Emergency room services | <1% | 12 | $347.20 |
| 86592 | <1% | 53 | $342.65 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 30 | $335.53 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 12 | $235.44 |
| 87210 | <1% | 25 | $220.25 | |
| 99156 | <1% | 56 | $218.00 | |
| 87070 | <1% | 12 | $165.48 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 19 | $146.30 |
| 87045 | <1% | 12 | $117.04 | |
| 82952 | <1% | 17 | $106.59 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 13 | $90.06 |
| 83970 | <1% | 12 | $74.21 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 14 | $69.49 |
| 96379 | <1% | 803 | $55.50 | |
| 87046 | <1% | 12 | $32.40 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 29 | $8.23 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 30 | $8.20 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $2.89 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVRANJES, MATKO (CEO)